Spelling suggestions: "subject:"small animal"" "subject:"tmall animal""
51 |
Das Bildgeführte Präzisionsbestrahlungsgerät für Kleintiere (SAIGRT): von der Entwicklung bis zur PraxisreifeTillner, Falk 22 April 2020 (has links)
Das entwickelte Bildgeführte Präzisionsbestrahlungsgerät für Kleintiere (engl. Small Animal Image-Guided Radiation Therapy – SAIGRT) dient der schnellen, hochauflösenden Röntgenbildgebung und präzisen, konformalen Bestrahlung von Kleintieren im Rahmen präklinischer in-vivo Experimente für die translationale Krebsforschung. Speziell programmierte Softwares zur Gerätesteuerung sowie zur Bildkorrektur- und Bildrekonstruktion auf dem zentralen leistungsfähigen Arbeitsplatz-PC stellen alle Gerätefunktionen zur Verfügung und ermöglichen durch automatisierte Abläufe und intuitive grafische Nutzeroberflächen eine einfache, sichere Bedienung. Für die Bestrahlungsplanung wird eine vollwertige, aus der humanen klinischen Strahlentherapie adaptierte 3D-Bestrahlungsplanungssoftware eingesetzt, die etablierte Werkzeuge für den Transfer und die Koregistrierung multimodaler Bilddaten, die Konturierung und Segmentierung von Zielvolumina und Risikoorganen sowie die Erstellung und Validierung von Bestrahlungsplänen enthält. Die resultierende Dosisverteilung wird darin basierend auf dem individuellen CT-Datensatz des Versuchstieres und einem auf das SAIGRT angepassten Maschinenmodell mittels eines Monte-Carlo-Algorithmus exakt und realitätsnah simuliert. Durch geometrische Kalibrierungen und vielfältige Basisdatenmessungen für die Bildgebung und Bestrahlung im Rahmen der Gerätekommissionierung ist eine Zielgenauigkeit von ca. ±0,1 mm mit hoher geometrischer Abbildungstreue und guter Bildqualität bei Bildgebungsdosen vergleichbar denen klinischer Radiografie- und CT-Geräte möglich. Die Dosisverteilung zur Bestrahlung der Versuchstiere spiegelt bei der definierten Strahlungsqualität größenskaliert die humane Strahlentherapie mit hochenergetischer Photonenstrahlung von klinischen Linearbeschleunigern wider. Ein umfassendes Qualitätssicherungsprogramm bestehend aus regelmäßiger Wartung und wiederkehrenden Konstanzprüfungen der Bildgebung und Bestrahlung sichert dauerhaft den technisch einwandfreien Zustand und die ordnungsgemäße Verfügbarkeit aller Gerätefunktionen in gleichbleibender Güte. Das SAIGRT ist somit nachweislich geeignet, bildgeführte Bestrahlungen mit einem Ablauf analog dem einer modernen klinischen Strahlentherapie am Menschen in präklinischen in-vivo Experimenten präzise an Kleintieren zu applizieren. Es leistet dadurch einen essentiellen Beitrag zur translationalen Krebsforschung in Dresden, indem die klinische Situation realistischer modelliert und so potenziell die Übertragbarkeit der Ergebnisse auf Krebspatienten verbessert werden kann. / The Small Animal Image-Guided Radiation Therapy (SAIGRT) platform facilitates fast, high resolution X-ray imaging and precise, conformal irradiation of small animals in preclinical in-vivo experiments for translational cancer research. Dedicated software for device control as well as image correction and reconstruction on a central high performance PC provide all device functions and allow simple and safe operation by automated procedures and intuitive graphical user interfaces. A fully 3D treatment planning software adapted from human clinical radiation therapy is used for treatment planning, containing established tools and methods for the transfer and registration of multimodality imaging data, contouring and segmentation of target volumes and organs at risk as well as creation and evaluation of treatment plans. Based on an individual CT scan of the small animal and a machine model adapted for the SAIGRT, the resulting dose distribution is simulated by a Monte-Carlo algorithm in a precise and realistic manner. Geometrical calibrations as well as manifold basic data measurements for X-ray imaging and irradiation during commissioning resulted in a targeting and imaging accuracy of about ±0.1 mm, a correct representation of imaging geometry and a good image quality with imaging doses comparable with those of clinical radiography and CT systems. Dose distribution of the defined beam quality used for irradiation of small animals reflects a downsized human radiation therapy using high energy photon beams of clinical linear accelerators. A comprehensive quality assurance program comprising regular maintenance and periodic constancy tests of X-ray imaging and irradiation ensures permanent technically perfect condition and proper availability of all implemented functions in a stable high quality. The SAIGRT platform is feasible for image-guided irradiations precisely applied to small animals in preclinical in-vivo experiments using a workflow of modern human radiation oncology. Thus, it significantly contributes to translational cancer research by more realistic modelling the clinical situation and potentially brings the results closer to their clinical implementation.
|
52 |
Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(−)-[18F]Fluspidine in GlioblastomaToussaint, Magali, Deutscher-Conrad, Winnie, Kranz, Mathias, Fischer, Steffen, Ludwig, Friedrich-Alexander, Juratli, Tareq A., Patt, Marianne, Wünsch, Bernhard, Schackert, Gabriele, Sabri, Osama, Brust, Peter 20 April 2023 (has links)
Glioblastoma multiforme (GBM) is the most devastating primary brain tumour characterised by infiltrative growth and resistance to therapies. According to recent research, the sigma-1 receptor (sig1R), an endoplasmic reticulum chaperone protein, is involved in signaling pathways assumed to control the proliferation of cancer cells and thus could serve as candidate for molecular characterisation of GBM. To test this hypothesis, we used the clinically applied sig1R-ligand (S)-(−)-[18F]fluspidine in imaging studies in an orthotopic mouse model of GBM (U87-MG) as well as in human GBM tissue. A tumour-specific overexpression of sig1R in the U87-MG model was revealed in vitro by autoradiography. The binding parameters demonstrated target-selective binding according to identical KD values in the tumour area and the contralateral side, but a higher density of sig1R in the tumour. Different kinetic profiles were observed in both areas, with a slower washout in the tumour tissue compared to the contralateral side. The translational relevance of sig1R imaging in oncology is reflected by the autoradiographic detection of tumour-specific expression of sig1R in samples obtained from patients with glioblastoma. Thus, the herein presented data support further research on sig1R in neuro-oncology.
|
53 |
An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatmentHübner, Doreen, Rieger, Christiane, Bergmann, Ralf, Ullrich, Martin, Meister, Sebastian, Toma, Marieta, Wiedemuth, Ralf, Temme, Achim, Novotny, Vladimir, Wirth, Manfred, Bachmann, Michael, Pietzsch, Jens, Fuessel, Susanne 05 June 2018 (has links) (PDF)
Background
Novel theranostic options for high-risk non-muscle invasive bladder cancer are urgently needed. This requires a thorough evaluation of experimental approaches in animal models best possibly reflecting human disease before entering clinical studies. Although several bladder cancer xenograft models were used in the literature, the establishment of an orthotopic bladder cancer model in mice remains challenging.
Methods
Luciferase-transduced UM-UC-3LUCK1 bladder cancer cells were instilled transurethrally via 24G permanent venous catheters into athymic NMRI and BALB/c nude mice as well as into SCID-beige mice. Besides the mouse strain, the pretreatment of the bladder wall (trypsin or poly-L-lysine), tumor cell count (0.5 × 106–5.0 × 106) and tumor cell dwell time in the murine bladder (30 min – 2 h) were varied. Tumors were morphologically and functionally visualized using bioluminescence imaging (BLI), magnetic resonance imaging (MRI), and positron emission tomography (PET).
Results
Immunodeficiency of the mouse strains was the most important factor influencing cancer cell engraftment, whereas modifying cell count and instillation time allowed fine-tuning of the BLI signal start and duration – both representing the possible treatment period for the evaluation of new therapeutics. Best orthotopic tumor growth was achieved by transurethral instillation of 1.0 × 106 UM-UC-3LUCK1 bladder cancer cells into SCID-beige mice for 2 h after bladder pretreatment with poly-L-lysine. A pilot PET experiment using 68Ga-cetuximab as transurethrally administered radiotracer revealed functional expression of epidermal growth factor receptor as representative molecular characteristic of engrafted cancer cells in the bladder.
Conclusions
With the optimized protocol in SCID-beige mice an applicable and reliable model of high-risk non-muscle invasive bladder cancer for the development of novel theranostic approaches was established.
|
54 |
An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatmentHübner, Doreen, Rieger, Christiane, Bergmann, Ralf, Ullrich, Martin, Meister, Sebastian, Toma, Marieta, Wiedemuth, Ralf, Temme, Achim, Novotny, Vladimir, Wirth, Manfred, Bachmann, Michael, Pietzsch, Jens, Fuessel, Susanne 05 June 2018 (has links)
Background
Novel theranostic options for high-risk non-muscle invasive bladder cancer are urgently needed. This requires a thorough evaluation of experimental approaches in animal models best possibly reflecting human disease before entering clinical studies. Although several bladder cancer xenograft models were used in the literature, the establishment of an orthotopic bladder cancer model in mice remains challenging.
Methods
Luciferase-transduced UM-UC-3LUCK1 bladder cancer cells were instilled transurethrally via 24G permanent venous catheters into athymic NMRI and BALB/c nude mice as well as into SCID-beige mice. Besides the mouse strain, the pretreatment of the bladder wall (trypsin or poly-L-lysine), tumor cell count (0.5 × 106–5.0 × 106) and tumor cell dwell time in the murine bladder (30 min – 2 h) were varied. Tumors were morphologically and functionally visualized using bioluminescence imaging (BLI), magnetic resonance imaging (MRI), and positron emission tomography (PET).
Results
Immunodeficiency of the mouse strains was the most important factor influencing cancer cell engraftment, whereas modifying cell count and instillation time allowed fine-tuning of the BLI signal start and duration – both representing the possible treatment period for the evaluation of new therapeutics. Best orthotopic tumor growth was achieved by transurethral instillation of 1.0 × 106 UM-UC-3LUCK1 bladder cancer cells into SCID-beige mice for 2 h after bladder pretreatment with poly-L-lysine. A pilot PET experiment using 68Ga-cetuximab as transurethrally administered radiotracer revealed functional expression of epidermal growth factor receptor as representative molecular characteristic of engrafted cancer cells in the bladder.
Conclusions
With the optimized protocol in SCID-beige mice an applicable and reliable model of high-risk non-muscle invasive bladder cancer for the development of novel theranostic approaches was established.
|
Page generated in 0.0416 seconds